Keely Macmillan, MSPH

home / authors / keely-macmillan-msph

Articles

Macmillan

June 19th 2021

Biosimilars Drive Savings in Medicare’s Oncology Care Model

Keely Macmillan, MSPH

Three Ways COVID-19 Makes the Oncology Care First Model More Attractive

October 29th 2020

Three Ways COVID-19 Makes the Oncology Care First Model More Attractive

Keely Macmillan, MSPH

COVID-19 has delayed the transition to Oncology Care First, but the forthcoming model could help.

Rethinking Downside Risk Protection Amid Growth in Precision Medicine

August 16th 2020

Rethinking Downside Risk Protection Amid Growth in Precision Medicine

Keely Macmillan, MSPH

Oncology drug costs affect those entering into risk-based arrangements, and these groups must rethink their approach to evaluating risk.

Latest Updated Articles

FDA approval stamp | Image Credit: Surendra - stock.adobe.com

Published: November 15th 2024 | Updated: November 19th 2024

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

What We’re Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Program for Elderly Care; Health Care Not a Top Issue Among Voters

Published: April 1st 2024 | Updated: November 5th 2024

What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues

Clinician giving patient a diagnosis | Image Credit: Pcess609 - stock.adobe.com

Published: October 21st 2024 | Updated: October 24th 2024

Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions

Hurricane | Image credit: Satoshi Kina - stock.adobe.com

Published: September 26th 2024 | Updated: October 1st 2024

Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health

Opdivo packaging | Image credit: Bristol Myers Squibb

Published: May 9th 2024 | Updated: May 21st 2024

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors

Glaucoma | Image credit: Alessandro Grandini - stock.adobe.com

Published: November 21st 2024 | Updated: November 23rd 2024

Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions